The companies said on Tuesday that Danaher will pay $180 per share to buy Masimo. The offer represents a premium of 38.3% to Masimo's last close.
In this article
Danaher
will acquire pulse oximeter maker Masimo
in a $9.9 billion deal, as the life science firm looks to bulk up its diagnostics portfolio.
The companies said on Tuesday that Danaher will pay $180 per share to buy Masimo. The offer represents a premium of 38.3% to Masimo's last close.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Boston Scientific said on Thursday it will buy medtech firm Penumbra in a deal valued at about $14.5 billion to expand its…
Chipmaker AMD agreed on Monday to sell the data center infrastructure manufacturing business of recently acquired ZT Systems to…
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in…
